إعلان
إعلان
SYRE
Spyre Therapeutics, Inc. Common Stock
30.62
USDبرعاية
+0.48
+1.59%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
30.98
+0.37
+1.20%
تقارير أرباح SYRE
النسبة الإيجابية المفاجئة
SYRE تفوق 17 من 39 آخر التقديرات.
44%
التقرير التالي
بيانات التقرير القادم
٢٥ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.78
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/+420.00%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/-3.70%
Spyre Therapeutics, Inc. Common Stock earnings per share and revenue
On ٠٤ نوفمبر ٢٠٢٥, SYRE reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.76 USD, resulting in a 80.30% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.57% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 المحللين forecast an EPS of -0.78 USD, with revenue projected to reach -- USD, implying an زيادة of 420.00% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
What were Spyre Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Spyre Therapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 80.3%, and revenue of $0.00, 0% as expectations.
How did the market react to Spyre Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -0.57%, changed from $22.98 before the earnings release to $22.85 the day after.
When is Spyre Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ٢٥ فبراير ٢٠٢٦.
What are the forecasts for Spyre Therapeutics, Inc. Common Stock's next earnings report?
Based on 15
المحللين, Spyre Therapeutics, Inc. Common Stock is expected to report EPS of -$0.78 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان